+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Type 1 Diabetes Drug Market - Global Forecast to 2030- Product Image
Type 1 Diabetes Drug Market - Global Forecast to 2030- Product Image
Sale

Type 1 Diabetes Drug Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4985893
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Type 1 Diabetes Drug Market grew from USD 19.14 billion in 2024 to USD 20.93 billion in 2025. It is expected to continue growing at a CAGR of 9.09%, reaching USD 32.27 billion by 2030.

The type 1 diabetes landscape is undergoing a profound evolution driven by breakthroughs in pharmacology, technology, and patient-centric strategies. As stakeholders navigate an increasingly complex environment, understanding the interplay of novel therapeutics, delivery mechanisms, reimbursement models, and regulatory shifts becomes essential. This executive summary delivers a concise yet comprehensive overview of the forces shaping the contemporary type 1 diabetes market, spotlighting pivotal innovations and strategic considerations for decision-makers. By synthesizing recent developments across drug classes, routes of administration, and service offerings, this introduction establishes a foundation for appreciating the sector’s transformative momentum and preparing for the challenges and opportunities that lie ahead.

Transformative Shifts Redefining Treatment Pathways

In recent years, integration of advanced biologics, digital health platforms, and combination regimens has rewritten treatment paradigms. Precision dosing techniques leveraging continuous glucose monitoring data have enhanced glycemic control, while smart insulin pens paired with mobile applications enable real-time adherence tracking. Advances in immunomodulatory agents and cell therapies promise disease‐modifying potential beyond mere glucose regulation. At the same time, regulatory bodies are streamlining pathways for breakthrough therapies, creating a fertile environment for rapid innovation.

Concurrently, patient empowerment through telemedicine consultations and education programs has shifted care models from reactive to proactive, driving improved outcomes. Stakeholders must align strategies to this new normal, where seamless connectivity between patients, providers, and payers underpins value creation. As a result, the market is moving from legacy insulin formulations to integrated solutions that combine drug efficacy with digital support, marking a pivotal shift from product‐centric to ecosystem-centric approaches.

Cumulative Impact of United States Tariffs 2025 on Access and Innovation

The introduction of increased United States tariffs in 2025 has altered the import and pricing landscape for type 1 diabetes therapies. Manufacturers that rely on international supply chains have had to absorb or pass through these levies, prompting strategic reviews of sourcing, production, and distribution. Some companies have accelerated onshore partnerships or invested in domestic manufacturing to mitigate duty impacts and maintain competitive pricing.

Meanwhile, payers have responded by tightening formulary access and favoring drugs produced within North America or those covered by preferential trade agreements. These formulary adjustments have driven steeper discount negotiations and influenced prescribing behavior toward locally sourced or tariff‐exempt products. At the same time, R&D budgets have been recalibrated to offset margin pressures, with several sponsors prioritizing high-value candidates most likely to achieve premium reimbursement. The cumulative effect is a marketplace marked by greater vertical integration, reshaped supply chains, and intensified competition among therapy innovators.

Key Segmentation Insights Driving Market Differentiation

A granular look at market segmentation reveals nuanced drivers across twelve analytical lenses. Based on drug class, stakeholders evaluate therapies spanning Amylin Analogs, Combination Drugs, DPP4 Inhibitors, Incretin Mimetics, Insulin, and SGLT2 Inhibitors to align clinical profiles with patient needs. When assessing product type, decision-makers contrast Combination Drugs with Generic Drugs and Patented Drugs to balance cost efficiency against differentiation. Examination by route of administration differentiates Inhalable, Injectable, and Oral options, each offering distinct adherence and bioavailability benefits. Formulation insights dissect the market into Capsule, Injectable Solution, Liquid Solution, and Tablet delivery formats.

Patient age group segmentation distinguishes Adults, Geriatrics, and Pediatrics, guiding dosage strategies and support services. Distribution channel analysis incorporates Hospitals, Online Pharmacies, Pharmacy Benefit Managers, Retail Pharmacies, and Wholesalers & Distributors to map patient access pathways. End user distinctions among Healthcare Providers, Patients, and Pharmaceutical Companies shape product development and marketing approaches. Efficacy and safety metrics focus on Glycemic Control, Patient Compliance, and Side Effect Profile to support evidence-based adoption. Technological advancement segmentation spotlights Continuous Glucose Monitoring Systems, including Flash Systems and Real-Time Systems, as well as Smart Insulin Pens to drive connectivity. Pricing strategy considerations compare Cost-Plus Pricing, Premium Pricing, and Value-Based Pricing to optimize revenue and market penetration. Research and development analysis spans Clinical Trials, Innovative Therapies, and Regulatory Approvals to gauge pipeline strength. Finally, patient care services assessment covers 24/7 Customer Support, Education & Awareness Programs, and Telemedicine Consultations to bolster patient engagement.

Key Regional Insights Shaping Market Dynamics

Regional dynamics in the type 1 diabetes arena reflect varied healthcare infrastructures, reimbursement frameworks, and demographic profiles. In the Americas, robust private-public partnerships and mature payers foster early adoption of advanced therapeutics and integrated care models, though affordability remains a critical concern in underserved communities. In Europe, the Middle East & Africa, heterogeneity in regulatory alignment and funding levels shapes a patchwork of access, where countries with centralized procurement exhibit faster uptake of standardized therapies, while emerging markets grapple with supply constraints.

Asia-Pacific stands out for its rapid digital health proliferation, driven by increasing mobile penetration and government incentives for telemedicine. Local manufacturing hubs in India and China are scaling generic insulin and biosimilar production, exerting downward price pressure while expanding access. Cross-regional collaborations, including licensure agreements and joint ventures, have emerged as key mechanisms to share best practices and accelerate deployment of combination therapies and monitoring systems.

Key Company Insights Shaping Competitive Advantage

Competitive intensity in the type 1 diabetes space is exemplified by a global roster of pharmaceutical and biotech leaders. Astellas Pharma Inc. and AstraZeneca PLC continue to refine their biologics platforms to enhance targeting and dosing precision. B. Braun Melsungen AG leverages its infusion technology expertise to optimize injectable delivery, while Biocon Limited expands its biosimilar insulin franchise across emerging markets. Daiichi Sankyo Company, Limited invests in novel peptide analogs to complement existing regimens.

Eli Lilly and Company and Sanofi S.A. remain cornerstone players, each integrating digital adherence tools with legacy insulin offerings. GSK plc and Novartis AG collaborate with tech partners to co-develop connected devices, whereas Johnson & Johnson Services, Inc. focuses on patient support programs to boost real-world outcomes. Novo Nordisk A/S strengthens its leadership in smart pens and continuous monitoring, and Pfizer Inc. explores combination therapies targeting multi-mechanistic control. Samsung Bioepis Co., Ltd. advances biosimilar solutions with emphasis on affordability, while Teva Pharmaceutical Industries Ltd. expands its generic portfolio to capture value segments. XOMA Corporation champions innovative immunotherapies aiming for disease remission rather than symptomatic management.

Actionable Recommendations for Industry Leaders

Industry leaders can seize market opportunities by aligning R&D investments with patient‐centric outcomes and operational resilience. Prioritizing modular manufacturing capabilities in key geographies will mitigate tariff-related disruptions and streamline supply chains. Collaborations between device and drug innovators should accelerate integrated solution development, enhancing adherence and generating differentiated clinical value.

To address diverse patient needs, companies must tailor pricing strategies-employing cost-plus models in price-sensitive segments while leveraging value-based arrangements in advanced care settings. Strengthening relationships with pharmacy benefit managers and hospital systems through outcomes-based contracting can secure formulary positioning. Concurrently, expanding telemedicine consultations and education programs will drive engagement in adults, geriatrics, and pediatric subpopulations.

Finally, fostering regulatory alignment via early dialogue and real-world evidence generation will expedite approvals for novel therapies and digital health tools. By adopting these recommendations, organizations can improve market access, sustain profitability, and deliver superior patient outcomes.

Conclusion: Charting the Path Forward in Type 1 Diabetes Care

As the type 1 diabetes market advances, stakeholders must embrace a holistic approach that integrates therapeutic innovation, technology adoption, and patient care optimization. Strategic foresight in supply chain design, segmentation alignment, and pricing will differentiate winners from followers. By continuously monitoring regional trends and competitor moves, organizations can adapt swiftly to regulatory shifts and payer demands. Ultimately, success hinges on delivering measurable clinical and economic benefits that resonate with providers, payers, and patients alike.

Market Segmentation & Coverage

This research report categorizes the Type 1 Diabetes Drug Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Amylin Analogs
  • Combination Drugs
  • DPP4 Inhibitors
  • Incretin Mimetics
  • Insulin
  • SGLT2 Inhibitors
  • Combination Drugs
  • Generic Drugs
  • Patented Drugs
  • Inhalable
  • Injectable
  • Oral
  • Capsule
  • Injectable
  • Liquid Solution
  • Tablet
  • Adults
  • Geriatrics
  • Pediatrics
  • Hospitals
  • Online Pharmacies
  • Pharmacy Benefit Managers (PBMs)
  • Retail Pharmacies
  • Wholesalers & Distributors
  • Healthcare Providers
  • Patients
  • Pharmaceutical Companies
  • Glycemic Control
  • Patient Compliance
  • Side Effect Profile
  • Continuous Glucose Monitoring Systems
    • Flash Systems
    • Real-Time Systems
  • Smart Insulin Pens
  • Cost-Plus Pricing
  • Premium Pricing
  • Value-Based Pricing
  • Clinical Trials
  • Innovative Therapies
  • Regulatory Approvals
  • 24/7 Customer Support
  • Education & Awareness Programs
  • Telemedicine Consultations

This research report categorizes the Type 1 Diabetes Drug Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Type 1 Diabetes Drug Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • B. Braun Melsungen AG
  • Biocon Limited
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • XOMA Corporation

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Type 1 Diabetes Drug Market, by Drug Class
8.1. Introduction
8.2. Amylin Analogs
8.3. Combination Drugs
8.4. DPP4 Inhibitors
8.5. Incretin Mimetics
8.6. Insulin
8.7. SGLT2 Inhibitors
9. Type 1 Diabetes Drug Market, by Product Type
9.1. Introduction
9.2. Combination Drugs
9.3. Generic Drugs
9.4. Patented Drugs
10. Type 1 Diabetes Drug Market, by Route Of Administration
10.1. Introduction
10.2. Inhalable
10.3. Injectable
10.4. Oral
11. Type 1 Diabetes Drug Market, by Formulation
11.1. Introduction
11.2. Capsule
11.3. Injectable
11.4. Liquid Solution
11.5. Tablet
12. Type 1 Diabetes Drug Market, by Patient Age Group
12.1. Introduction
12.2. Adults
12.3. Geriatrics
12.4. Pediatrics
13. Type 1 Diabetes Drug Market, by Distribution Channel
13.1. Introduction
13.2. Hospitals
13.3. Online Pharmacies
13.4. Pharmacy Benefit Managers (PBMs)
13.5. Retail Pharmacies
13.6. Wholesalers & Distributors
14. Type 1 Diabetes Drug Market, by End User
14.1. Introduction
14.2. Healthcare Providers
14.3. Patients
14.4. Pharmaceutical Companies
15. Type 1 Diabetes Drug Market, by Efficacy & Safety
15.1. Introduction
15.2. Glycemic Control
15.3. Patient Compliance
15.4. Side Effect Profile
16. Type 1 Diabetes Drug Market, by Technological Advancements
16.1. Introduction
16.2. Continuous Glucose Monitoring Systems
16.2.1. Flash Systems
16.2.2. Real-Time Systems
16.3. Smart Insulin Pens
17. Type 1 Diabetes Drug Market, by Pricing Strategy
17.1. Introduction
17.2. Cost-Plus Pricing
17.3. Premium Pricing
17.4. Value-Based Pricing
18. Type 1 Diabetes Drug Market, by Research & Development
18.1. Introduction
18.2. Clinical Trials
18.3. Innovative Therapies
18.4. Regulatory Approvals
19. Type 1 Diabetes Drug Market, by Patient Care Services
19.1. Introduction
19.2. 24/7 Customer Support
19.3. Education & Awareness Programs
19.4. Telemedicine Consultations
20. Americas Type 1 Diabetes Drug Market
20.1. Introduction
20.2. Argentina
20.3. Brazil
20.4. Canada
20.5. Mexico
20.6. United States
21. Asia-Pacific Type 1 Diabetes Drug Market
21.1. Introduction
21.2. Australia
21.3. China
21.4. India
21.5. Indonesia
21.6. Japan
21.7. Malaysia
21.8. Philippines
21.9. Singapore
21.10. South Korea
21.11. Taiwan
21.12. Thailand
21.13. Vietnam
22. Europe, Middle East & Africa Type 1 Diabetes Drug Market
22.1. Introduction
22.2. Denmark
22.3. Egypt
22.4. Finland
22.5. France
22.6. Germany
22.7. Israel
22.8. Italy
22.9. Netherlands
22.10. Nigeria
22.11. Norway
22.12. Poland
22.13. Qatar
22.14. Russia
22.15. Saudi Arabia
22.16. South Africa
22.17. Spain
22.18. Sweden
22.19. Switzerland
22.20. Turkey
22.21. United Arab Emirates
22.22. United Kingdom
23. Competitive Landscape
23.1. Market Share Analysis, 2024
23.2. FPNV Positioning Matrix, 2024
23.3. Competitive Analysis
23.3.1. Astellas Pharma Inc.
23.3.2. AstraZeneca PLC
23.3.3. B. Braun Melsungen AG
23.3.4. Biocon Limited
23.3.5. DAIICHI SANKYO COMPANY, LIMITED
23.3.6. Eli Lilly and Company
23.3.7. GSK plc
23.3.8. Johnson & Johnson Services, Inc.
23.3.9. Novartis AG
23.3.10. Novo Nordisk A/S
23.3.11. Pfizer Inc.
23.3.12. Samsung Bioepis Co., Ltd.
23.3.13. Sanofi S.A.
23.3.14. Teva Pharmaceutical Industries Ltd.
23.3.15. XOMA Corporation
24. ResearchAI
25. ResearchStatistics
26. ResearchContacts
27. ResearchArticles
28. Appendix
List of Figures
FIGURE 1. TYPE 1 DIABETES DRUG MARKET MULTI-CURRENCY
FIGURE 2. TYPE 1 DIABETES DRUG MARKET MULTI-LANGUAGE
FIGURE 3. TYPE 1 DIABETES DRUG MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2024 VS 2030 (%)
FIGURE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2024 VS 2030 (%)
FIGURE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2024 VS 2030 (%)
FIGURE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2024 VS 2030 (%)
FIGURE 28. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2024 VS 2030 (%)
FIGURE 30. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 34. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 36. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 37. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 38. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 39. TYPE 1 DIABETES DRUG MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 40. TYPE 1 DIABETES DRUG MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TYPE 1 DIABETES DRUG MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DPP4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INCRETIN MIMETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATENTED DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INHALABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY LIQUID SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PHARMACY BENEFIT MANAGERS (PBMS), BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY WHOLESALERS & DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY GLYCEMIC CONTROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT COMPLIANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SIDE EFFECT PROFILE, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY FLASH SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REAL-TIME SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY SMART INSULIN PENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY COST-PLUS PRICING, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PREMIUM PRICING, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY VALUE-BASED PRICING, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY INNOVATIVE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY REGULATORY APPROVALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY 24/7 CUSTOMER SUPPORT, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY EDUCATION & AWARENESS PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL TYPE 1 DIABETES DRUG MARKET SIZE, BY TELEMEDICINE CONSULTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 102. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 103. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 104. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 106. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 107. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 108. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 110. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 111. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 112. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 113. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 114. CANADA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 115. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 117. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 119. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 120. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 123. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 124. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 125. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 126. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 127. MEXICO TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES TYPE 1 DIABETES DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC TYPE 1 DIABETES DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 160. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 164. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 169. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 170. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 173. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 174. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 175. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 177. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 178. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 179. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 180. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 181. CHINA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 182. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 183. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 184. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 186. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 187. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 190. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 191. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 192. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 193. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 194. INDIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 195. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 197. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 208. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 209. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 210. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 212. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 216. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 217. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 218. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 219. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 220. JAPAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 221. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 222. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 223. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 225. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 226. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 227. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 229. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 230. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 231. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 232. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 233. MALAYSIA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 234. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 235. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 236. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 237. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 238. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 239. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 242. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 243. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 244. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 245. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 246. PHILIPPINES TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 247. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 248. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 249. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 251. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 252. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 255. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 256. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 257. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 258. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 259. SINGAPORE TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 260. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 261. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 262. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 264. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 265. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 273. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 274. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 275. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 276. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 277. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 278. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 281. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 282. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 283. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 284. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 285. TAIWAN TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 286. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 287. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 288. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 290. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 291. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 294. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 295. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 296. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 297. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 298. THAILAND TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 299. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 300. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 301. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 302. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 303. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 304. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 307. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 308. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)
TABLE 309. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
TABLE 310. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY RESEARCH & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 311. VIETNAM TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT CARE SERVICES, 2018-2030 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 314. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 316. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 317. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 318. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY EFFICACY & SAFETY, 2018-2030 (USD MILLION)
TABLE 320. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 321. EUROPE, MIDDLE EAST & AFRICA TYPE 1 DIABETES DRUG MARKET SIZE, BY CONTINUOUS GLUCOSE MONITORING SYSTEMS, 2018-2030 (USD MILLION)

Companies Mentioned

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • B. Braun Melsungen AG
  • Biocon Limited
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eli Lilly and Company
  • GSK plc
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • XOMA Corporation

Methodology

Loading
LOADING...

Related Topics

Related Reports

Type 1 Diabetes: Epidemiology Forecast to 2033 - Product Image

Type 1 Diabetes: Epidemiology Forecast to 2033

  • Report
  • 69 Pages
  • Global
From
Diabetes Drugs Market - Global Forecast to 2030 - Product Image

Diabetes Drugs Market - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Type 2 Diabetes Drugs Market - Global Forecast to 2030 - Product Image

Type 2 Diabetes Drugs Market - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Diabetes Type (Type 1, 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, with Growth Forecasts, 2025-2030 - Product Image

Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Diabetes Type (Type 1, 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 159 Pages
  • Global
From

About the Type 1 Diabetes Drug Market

The Type 1 Diabetes Drug market is a subset of the Immune Disorders Drugs market. It is composed of drugs used to treat Type 1 Diabetes, an autoimmune disorder in which the body's immune system attacks the cells that produce insulin. These drugs are used to help regulate blood sugar levels and reduce the risk of complications associated with the disease. Commonly used Type 1 Diabetes Drugs include insulin, sulfonylureas, meglitinides, and GLP-1 agonists. These drugs are typically administered orally or through injection. The Type 1 Diabetes Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.